US start-up secures US$2.68m to address pelvic health concerns

Source: FemTech World US startup Pelvital secures $2.68M to address pelvic health concerns. This seed funding will support the development and market reach of their innovative medical devices designed to improve women's health.

The Flyte intravaginal device aims to treat stress urinary incontinence and strengthen pelvic floor muscles.

The US women’s health start-up Pelvital has raised US$2.68m in seed funding to address stress urinary incontinence and pelvic health concerns.

The Minnesota-based company aims to restore pelvic health with its first product Flyte, an at-home intravaginal device that treats stress urinary incontinence and strengthens pelvic floor muscles.

Originally developed by physicians from the Arctic University of Norway, the product uses mechanotherapy, a treatment modality that when paired with an active pelvic floor contraction stimulates tissue regeneration and the creation of neuromuscular memory.

New figures suggest that six in ten women are living with at least one symptom of poor pelvic floor health, such as urinary incontinence or pelvic organ prolapse — yet 69 per cent have never mentioned these to an NHS professional, according to a recent survey by the Royal College of Obstetricians and Gynaecologists (RCOG).

In the US, around 25 per cent of women reported one or more pelvic floor disorder, with urinary incontinence being the most common disorder reported.